# Tearscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tearscience

- Industry: Medical Devices & Equipment
- Headquarters: Morrisville, US
- Website: www.tearscience.com
- Total disclosed funding: $74M
- Latest round: Series D (Mar 31, 2016)
- Investors on record: 6

## About

Tearscience, Inc. specializes in ocular health through advanced technologies and services aimed at treating Meibomian Gland Dysfunction (MGD), enhancing the quality of life for patients suffering from chronic eye conditions.Tearscience, Inc. is focused on treating Meibomian Gland Dysfunction, established in 2005 and headquartered in Morrisville, US. The company has undergone no known strategic pivots and remains an independent entity. The founder's history is not publicly available, and the company has raised USD 19.23 mn in Series D funding, with a total amount raised of USD 19.23 mn and a current valuation of USD 50.106 mn, with Essex Woodlands as the latest investor. The most recent deal occurred on March 31, 2016.Tearscience, Inc. provides innovative solutions for ocular health, focusing on Meibomian Gland Dysfunction. Their flagship product, the TearScience™ technology, aids healthcare professionals in managing ocular surface issues, particularly in patients experiencing discomfort from contact lenses. The company markets its products globally, catering to eye care practitioners, optometrists, and ophthalmologists across North America, Europe, and Asia-Pacific, enhancing patient outcomes through evidence-based practices.Revenue generation at Tearscience, Inc. is achieved through direct sales to healthcare providers, partnerships with optometry practices, and collaborations with wholesalers and retailers. The company leverages its TearScience™ technology alongside products like ACUVUE® contact lenses to foster business transactions, focusing on B2B partnerships within the eye care sector. The revenue model is supported by both continuous sales of consumable products and one-time transactions for technological solutions, reflecting a multifaceted approach to ocular health management.Tearscience, Inc. plans to utilize the USD 19.23 mn raised in their Series D financing to enhance their product offerings and support market expansion. The company is focused on the launch of new technologies aimed at improving the treatment of Meibomian Gland Dysfunction, with plans to enter additional markets in North America and Europe by the end of 2023. The recent funding will be allocated towards research and development, marketing initiatives, and expanding their distribution networks to reach a wider audience in the eye care sector.

## Funding rounds

- Series D, Mar 31, 2016, $19M — Essex Woodlands
- Series C, May 4, 2010, $40M — Essex Woodlands, Spray Venture Partners, Quaker Partners Management, General Catalyst Partners, De Novo Ventures, Patricia Industries
- Series B, Sep 20, 2007, $0.3M — Spray Venture Partners, De Novo Ventures
- Series B, Dec 19, 2006, $15M — Spray Venture Partners, Quaker Partners Management, De Novo Ventures

## Investors

- Spray Venture Partners (https://capitalatlas.ai/funds/spray-venture-partners) — Series B, Series C
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B, Series C
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series B, Series C
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series D
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series C
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series C